SCHEMBL8570573

SCHEMBL8570573

c1ccc(CC2CCN(Cc3ccc[nH]3)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 3/20 0.67
ATM Q13315 4/20 0.59
ALDH1A1 P00352 3/20 0.58
DRD2 P14416 1/20 0.56
DRD4 P21917 1/20 0.56
DRD3 P35462 1/20 0.56
GRIN1 Q05586 1/20 0.55
GRIN2B Q13224 1/20 0.55
KDM4E B2RXH2 1/20 0.55
GLA P06280 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HRH3 Q9Y5N1 1/20 0.54
PRMT3 O60678 1/20 0.54
CARM1 Q86X55 1/20 0.54
PRMT6 Q96LA8 1/20 0.54
PRMT1 Q99873 1/20 0.54
PRMT8 Q9NR22 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Maleic Acid SCHEMBL8569150 0.90 CCR3 (0.55) CCR3ATMALDH1A1GRIN1GRIN2B
Fumaric Acid SCHEMBL8569153 0.90 CCR3 (0.55) CCR3ATMALDH1A1GRIN1GRIN2B
SCHEMBL2004615 0.81 CCR3 (1.00) CCR3ATMALDH1A1KDM4EGLA
SCHEMBL5778870 0.81 ATM (0.61) CCR3ATMALDH1A1KDM4EGLA
SCHEMBL13375731 0.80 DRD2 (0.53) CCR3ATMDRD2DRD4DRD3
SCHEMBL7977320 0.79 CCR3 (0.96) CCR3ATMALDH1A1KDM4EGLA
SCHEMBL8191786 0.79 CCR3 (0.96) CCR3ATMALDH1A1KDM4EGLA
SCHEMBL3968181 0.77 DRD2 (0.73) DRD2DRD4DRD3SIGMAR1
SCHEMBL14375224 0.76 DRD2 (0.55) ALDH1A1DRD2DRD4DRD3HRH3
SCHEMBL8574775 0.76 GRIN2B (0.62) CCR3ATMALDH1A1GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5760234-A THERAPY FOR NERVOUS SYSTEM DISORDERS NEUROGEN CORPORATION (US) 1998-06-02 US disclosed
US-5750700-A COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SCHIZOPHRENIA, NEUROLEPTIC AGENTS FOR BINDING TO DOPAMINE RECEPTORS NEUROGEN CORPORATION (US) 1998-05-12 US disclosed